Literature DB >> 28379283

Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).

G Friberg1, D Reese1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28379283     DOI： 10.1093/annonc/mdx150

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats.

Authors:  Ming-Peng Fu; Zi-Long Guo; Hong-Ling Tang; Hui-Fen Zhu; Guan-Xin Shen; Yong He; Ping Lei
Journal:  Curr Med Sci       Date:  2020-03-13

2.  Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.

Authors:  Brian H Santich; Jeong A Park; Hoa Tran; Hong-Fen Guo; Morgan Huse; Nai-Kong V Cheung
Journal:  Sci Transl Med       Date:  2020-03-11       Impact factor: 17.956

Review 3.  Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.

Authors:  Leila Amini; Sara K Silbert; Nirali N Shah; Mohamed Abou-El-Enein; Shannon L Maude; Loretta J Nastoupil; Carlos A Ramos; Renier J Brentjens; Craig S Sauter
Journal:  Nat Rev Clin Oncol       Date:  2022-03-22       Impact factor: 66.675

4.  A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.

Authors:  Wing Keung Chan; Siwen Kang; Youssef Youssef; Erin N Glankler; Emma R Barrett; Alex M Carter; Elshafa H Ahmed; Aman Prasad; Luxi Chen; Jianying Zhang; Don M Benson; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Immunol Res       Date:  2018-05-16       Impact factor: 11.151

5.  Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.

Authors:  Benshang Li; Samuel W Brady; Xiaotu Ma; Shuhong Shen; Yingchi Zhang; Yongjin Li; Karol Szlachta; Li Dong; Yu Liu; Fan Yang; Ningling Wang; Diane A Flasch; Matthew A Myers; Heather L Mulder; Lixia Ding; Yanling Liu; Liqing Tian; Kohei Hagiwara; Ke Xu; Xin Zhou; Edgar Sioson; Tianyi Wang; Liu Yang; Jie Zhao; Hui Zhang; Ying Shao; Hongye Sun; Lele Sun; Jiaoyang Cai; Hui-Ying Sun; Ting-Nien Lin; Lijuan Du; Hui Li; Michael Rusch; Michael N Edmonson; John Easton; Xiaofan Zhu; Jingliao Zhang; Cheng Cheng; Benjamin J Raphael; Jingyan Tang; James R Downing; Ludmil B Alexandrov; Bin-Bing S Zhou; Ching-Hon Pui; Jun J Yang; Jinghui Zhang
Journal:  Blood       Date:  2020-01-02       Impact factor: 25.476

Review 6.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 7.  Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Authors:  Ciprian Tomuleasa; Shigeo Fuji; Cristian Berce; Anca Onaciu; Sergiu Chira; Bobe Petrushev; Wilhelm-Thomas Micu; Vlad Moisoiu; Ciprian Osan; Catalin Constantinescu; Sergiu Pasca; Ancuta Jurj; Laura Pop; Ioana Berindan-Neagoe; Delia Dima; Shigehisa Kitano
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

Review 8.  Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Authors:  Christiane Thallinger; Thorsten Füreder; Matthias Preusser; Gerwin Heller; Leonhard Müllauer; Christoph Höller; Helmut Prosch; Natalija Frank; Rafal Swierzewski; Walter Berger; Ulrich Jäger; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2017-11-02       Impact factor: 1.704

9.  Approach to the Adult Acute Lymphoblastic Leukemia Patient.

Authors:  Valentina Sas; Vlad Moisoiu; Patric Teodorescu; Sebastian Tranca; Laura Pop; Sabina Iluta; Sergiu Pasca; Cristina Blag; Sorin Man; Andrei Roman; Catalin Constantinescu; Ioana Rus; Mihail Buse; Bogdan Fetica; Mirela Marian; Cristina Selicean; Ioana Berindan-Neagoe; Bobe Petrushev; Horia Bumbea; Alina Tanase; Mihnea Zdrenghea; Shigeo Fuji; Shigehisa Kitano; Ciprian Tomuleasa
Journal:  J Clin Med       Date:  2019-08-06       Impact factor: 4.241

10.  The biological activity of bispecific trastuzumab/pertuzumab plant biosimilars may be drastically boosted by disulfiram increasing formaldehyde accumulation in cancer cells.

Authors:  Tatiana V Komarova; Ekaterina V Sheshukova; Ekaterina N Kosobokova; Vyacheslav S Kosorukov; Anastasia V Shindyapina; Fedor A Lipskerov; Polina S Shpudeiko; Tatiana E Byalik; Yuri L Dorokhov
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.